Details of the Drug

General Information of Drug (ID: DM04HNB)

Drug Name
Anti-CD19 CAR-T
Indication
Disease Entry ICD 11 Status REF
Haematopoietic/lymphoid cancer 2B33.5 Phase 1/2 [1]
Acute lymphoblastic leukaemia 2A85 Phase 1 [2]
B-cell chronic lymphocytic leukaemia 2A82.00 Phase 1 [2]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0KF9T
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Haematopoietic/lymphoid cancer
ICD Disease Classification 2B33.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
2 ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma